Skip to main content
GNPX
NASDAQ Life Sciences

Genprex Receives Formal Nasdaq Delisting Notice, Ineligible for Standard Compliance Period

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.644
Mkt Cap
$6.777M
52W Low
$0.624
52W High
$55
52W Position info
3.1% above low
Off High info
99% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GNPX is trading near its 52-week low of $0.624 (3.1% above the low) on light trading volume (0.3× avg).

Summary

Genprex, Inc. received a formal delisting notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period due to a recent reverse stock split.


Key Events · Corporate Governance and Compliance · GNPX

  • Formal Delisting Notice Received

    Genprex received a letter from Nasdaq on June 10, 2026, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.

  • Ineligible for Compliance Period

    Due to a reverse stock split effected on October 21, 2025, Nasdaq determined the company is not eligible for the standard 180-day compliance period.

  • Intent to Request Hearing

    Genprex intends to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action pending the hearing.

  • Potential for Another Reverse Split

    The company may consider another reverse stock split to regain compliance, a measure for which shareholders were already asked to approve in April 2026.


Analysis · GNPX · Life Sciences

This 8-K confirms Genprex has received a formal delisting notice from Nasdaq, a critical development following previous warnings and shareholder requests for another reverse stock split. The company's ineligibility for a standard compliance period, due to a prior reverse split in October 2025, significantly escalates the risk. While Genprex intends to request a hearing, there is no guarantee of continued listing, which could severely impact its ability to raise capital and its stock price, especially given its existing "going concern" warning.

At the time of this filing, GNPX was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.62 to $55.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GNPX - Latest Insights

GNPX
Jul 14, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.540
Real-time Price: $7.35 info
Change: Reverse Stock Split info
Market Cap: $3.944M info
GNPX
Jun 22, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $7.35 info
Change: Reverse Stock Split info
Market Cap: $3.944M info
GNPX
Jun 18, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.582401
Real-time Price: $7.35 info
Change: Reverse Stock Split info
Market Cap: $3.944M info
GNPX
Jun 12, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.645201
Real-time Price: $7.35 info
Change: Reverse Stock Split info
Market Cap: $3.944M info
GNPX
Jun 05, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.650
Real-time Price: $7.35 info
Change: Reverse Stock Split info
Market Cap: $3.944M info